MNPR (Monopar Therapeutics) Accounts Payable: $2.46 Mil (As of Mar. 2026)


MNPR Monopar Therapeutics Inc MNPR
35 GF Score
Price $97.50
! 3 Warning Signs
View Full Analysis

What is Monopar Therapeutics Accounts Payable?

Monopar Therapeutics MNPR +2.98% 35 Accounts Payable is $2.46 Mil as of Mar. 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Monopar Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $2.46 Mil.

Monopar Therapeutics's quarterly Accounts Payable increased from Sep. 2025 ($2.57 Mil) to Dec. 2025 ($2.74 Mil) but then declined from Dec. 2025 ($2.74 Mil) to Mar. 2026 ($2.46 Mil).

Monopar Therapeutics's annual Accounts Payable increased from Dec. 2023 ($1.76 Mil) to Dec. 2024 ($2.25 Mil) and increased from Dec. 2024 ($2.25 Mil) to Dec. 2025 ($2.74 Mil).

Monopar Therapeutics Accounts Payable Related Terms

Monopar Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics Accounts Payable Chart

Monopar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.76 2.25 2.74

Monopar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.49 1.58 2.57 2.74 2.46
MNPR
35GF Score
Monopar Therapeutics Inc MNPR
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $2.46 Mil mean?
Monopar Therapeutics (MNPR) has a Accounts Payable of $2.46 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Monopar Therapeutics and its competitors.
Is Monopar Therapeutics' Accounts Payable too high?
Monopar Therapeutics' current Accounts Payable is $2.46 Mil. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Accounts Payable compare to MDXG and FTH?
Monopar Therapeutics' Accounts Payable of $2.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current Accounts Payable is $2.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Accounts Payable of $2.46 Mil. The current Accounts Payable is $2.46 Mil. Monopar Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Accounts Payable is $2.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Other Exchanges 1IY0:Germany
Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score

Get the complete analysis for MNPR

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$97.50
Price